MoonLake Immunotherapeutics
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Arrangements
On October 26, 2025, Dr. Kristian Reich, the Chief Scientific Officer of the Company, terminated a trading plan that was originally adopted on June 26, 2025. This plan was intended to satisfy the affirmative defense of Rule 10b5-1(c) and provided for the sale, subject to certain conditions, of up to 300,000 Class A Ordinary Shares through March 31, 2026.
On December 10, 2025, Mr. Matthias Bodenstedt, the Chief Financial Officer of the Company, terminated a trading plan that was originally adopted on June 17, 2025. This plan was intended to satisfy the affirmative defense of Rule 10b-1(c) and provided for the sale, subject to certain conditions, of up to 300,000 Class A Ordinary Shares through March 31, 2026.
On December 10, 2025, Mr. Bodenstedt, the Chief Financial Officer of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b-1(c). Mr. Bodenstedt's plan provides for the sale, subject to certain conditions, of up to 385,870 Class A Ordinary Shares through December 31, 2026.
During the three months ended December 31, 2025, no other director or Section 16 officer of the Company adopted orterminated any“Rule 10b5-1 trading arrangement” or“non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.